RxDoctor Payments Data

Brian Civic, MD

Critical Care Medicine · Allentown, PANPI 1780844555

Payments from drug & device makers

$2,377in general payments, 2019–2025

Across 54 payments — averaging $44.02 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$1K
  • Bayer$131
  • Fisher & Paykel Healthcare Inc$124
  • GSK$110
  • Boehringer Ingelheim$74
  • Genentech USA, Inc.$73
  • plus $469 from 14 others

What the payments were for

  • Travel & lodging$46420%
  • Food & beverage$1,89880%
  • Gifts$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,377 in reported general payments places this provider in the 75th percentile of 354 critical care medicine providers in Pennsylvania.

See all critical care medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$57,345
Medicare patients
379
Services billed
836

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tyvaso DpiTreprostinil49$1,222,093
UptraviSelexipag58$1,034,356
OpsumitMacitentan31$390,969
Ambrisentan72$218,266
AdempasRiociguat16$214,813
OfevNintedanib Esylate21$212,555
TezspireTezepelumab-Ekko42$209,092
LetairisAmbrisentan13$159,378
Trelegy ElliptaFluticasone/Umeclidin/Vilanter71$78,262
Stiolto RespimatTiotropium Br/Olodaterol Hcl99$75,370
Sildenafil Citrate93$60,431
Breo ElliptaFluticasone/Vilanterol73$37,976
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr54$37,282
Spiriva RespimatTiotropium Bromide55$37,250
Advair HfaFluticasone Propion/Salmeterol42$18,869

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit$51$1,425,32589 claims
Boehringer IngelheimOfev, Stiolto Respimat, Spiriva Respimat, Striverdi Respimat$74$327,977186 claims
AstraZenecaTezspire, Symbicort, Bevespi Aerosphere$42$224,24488 claims
BayerAdempas$131$214,81316 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta$110$169,592230 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 354 critical care medicine providers in Pennsylvania.

Other critical care medicine in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →